Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daily tadalafil for benign prostatic hyperplasia symptoms
2008-002841-21Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in benign prostatic hyperplasia (BPH) comparing Tadalafil arm with Placebo arm (2 arms). Primary endpoint: Change in International Prostate Symptom Score (IPSS) from baseline at 12 weeks. Started Aug 2008; status: completed.
02
Drugs
tadalafil
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on 2008-002841-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002841-21.